In particular, the impaired NO production in dystrophin-deficient mdx mice is due to a disrupted mechanotransduction AMP-activated protein kinase (AMPK)-nNOS signaling, suggesting that AMPK may be a possible pharmacologic target to restore NO synthesis in DMD [24,25]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.